-150x150.jpg)
Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury’s out on whether the medications caused the eye trouble, according to a new small study. The study reviewed the cases of nine people who developed sight-robbing issues, such as dysfunction in blood vessels around the eye’s optic nerve, after taking a GLP-1. “We’re trying to elucidate if being on these drugs can increase your risk,” said study co-author Dr. Norah Lincoff. She’s a neuro-ophthalmologist and professor of neurology at the University at Buffalo. The study, published recently in JAMA Opthalmology, focused on nine patients, all in their 50s or 60s, who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as nonarteritic anterior ischemic optic neuropathy (NAION). This occurs when blood vessels fail to supply enough blood to the optic nerve, which is crucial for sight. In NAION, damage to the nerve can lead to a sudden and permanent partial loss of vision. Lead study author Dr. Bradley Katz, of the John A. Moran Eye Center at University of Utah Health in Salt Lake City, first noted the issue in a patient who experienced a sudden and painless loss of vision in one eye after starting seamglutide. The patient briefly halted use of the drug, but when… read on > read on >